[Efficacy and safety of ribavirin aerosol in children with hand-foot-mouth disease].

OBJECTIVE: To evaluate the efficacy and safety of ribavirin aerosol in children with hand-foot-mouth disease (HFMD). METHODS: A randomized, double-blind, placebo-controlled trial was performed. A total of 119 children with mild HFMD were randomly divided into an observed group (n=59) and a control group (n=60). In the observed group, ribavirin aerosol was given four times within the first hour, followed by once every other hour for the remaining time of the day and day 2; from days 3 to 7, it was given 4 times per day, with 2-3 sprays every time, for 7 days. In the control group, placebo was given in the same way as in the observed group. Additionally, both groups used oral antiviral liquid. The scores of clinical symptoms including oral ulcer, skin rash, nasal congestion, runny nose, sneezing, cough, and fever before and after treatment were recorded to evaluate treatment outcomes. Throat swabs were taken before treatment and 5-7 days after treatment to measure viral load by RT-PCR and to compare the negative conversion rate between the two groups. RESULTS: Fifty-seven patients in the observed group and 56 patients in the control group were tested according to the original research design. After 5-7 days of treatment, the observed group had a significantly higher overall negative conversion rate of enterovirus than the control group (P<0.01). The overall marked response rate and overall response rate of the observed group were 89% and 89%, respectively, significantly higher than those of the control group (29% and 43%). During treatment, there were no adverse reactions such as dizziness, vomiting, and notable decreases in hemoglobin, white blood cells, and platelets in the two groups. CONCLUSIONS: Ribavirin aerosol can be effectively and safely used for treating mild HFMD. With low dosage and few adverse reactions, it holds promise for clinical application.

Effect of the molecular mass of tremella polysaccharides on accelerated recovery from cyclophosphamide-induced leucopenia in rats.

The body of tremella were decocted with water, and hydrolyzed with 0.1 mol/L hydrochloric acid for different times, giving tremella polysaccharides with six molecular mass values. The structures of all the tremella polysaccharides had non-reducing terminals of ß-D-pyranglucuronide, the backbone was composed of (1 → 3)-linked ß-D-manno-pyranoside, and the side chain composed of (1 → 6)-linked ß-D-xylopyranoside was attached to the C(2) of the backbone mannopyranoside. Immunomodulatory effect studies indicated that tremella polysaccharides increased the counts of leukocytes in the peripheral blood which were significantly lowered by cyclophosphamide, and the lower the molecular mass of the tremella polysaccharide, the better this effect was.

[Significance of beta-catenin and Cyclin D1 express in glioma].

AIM: To investigate the expression and the significance of beta-catenin and Cyclin D1 in gliomas. METHODS: The SABC immunohistochemistry were used to detect the expression of beta-catenin and Cyclin D1 in 49 brain gliomas and 5 normal brain tissues. RESULTS: The beta-catenin positive ratio in normal brain tissues and glioma samples are 2/5 and 38/49(P<0.01) respectively, and the Cyclin D1 positive ratio in normal brain tissues and gliomas are 1/5 and 42/49(P<0.01); Compared with the normal brain tissue, both the immunohistochemical expression of beta-catenin and Cyclin D1 were up-regulated(P<0.05), and the expression of beta-catenin and Cyclin D1 between the normal brain tissues and gliomas exhibited significantly difference (P<0.01). CONCLUSION: beta-catenin and Cyclin D1 increased in gliomas may be precipitate the tumorigenesis of glioma.